Arsonoliposomes: effect of lipid composition on their stability and morphology.
The influence of the lipid composition of arsonoliposomes on their membrane integrity was investigated to evaluate whether it is possible to combine their action with drugs that can be encapsulated in their aqueous interior. This was investigated by measuring the retention of vesicle-encapsulated calcein (100 mM) during incubation, in the absence and presence of serum proteins. Liposomes containing various concentrations of arsonolipid (with the palmitoyl side chain) as well as egg-lecithin (phosphatidylcholine, PC) and cholesterol (lipid/chol 2:1 mol:mol) were prepared. In some experiments, PC was replaced by the synthetic phospholipid DSPC. All PC/arsonoliposomes tested are stable after 24 h of incubation in buffer at 37 degrees C. After incubation in the presence of serum proteins, arsonoliposomes that contain low amounts of arsonolipid (up to 5 mol% of the lipid content without cholesterol) are stable, whereas increased release of calcein is observed when vesicle arsonolipid concentration is raised (from 5 to 15 mol%). Further increase of arsonolipid content results in immediate decrease of calcein latency while the remaining calcein is rapidly released during incubation. DSPC/arsonoliposomes are comparably more stable, and membrane integrity is independent of the vesicle arsonolipid content, in the range investigated (15-40 mol% of the lipid content without cholesterol). Thereby, we conclude that more stable arsonoliposomes that incorporate high arsonolipid concentrations may be produced when PC is replaced by DSPC. The latter arsonoliposomes provide a system that may be used for combining arsonolipid activity with the activity of other drugs.
Piperoudi
Sophia
S
Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Patras, Greece.
Ioannou
Panayiotis V
PV
Frederik
Peter
P
Antimisiaris
Sophia G
SG
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000737:chemistry*; D002417:Cattle; D020285:Cryoelectron Microscopy; D004339:Drug Compounding; D005452:Fluoresceins / Q000737:chemistry; D005456:Fluorescent Dyes / Q000737:chemistry; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D010087:Oxides / Q000737:chemistry*
D000970:Antineoplastic Agents; D001152:Arsenicals; D005452:Fluoresceins; D005456:Fluorescent Dyes; D008055:Lipids; D008081:Liposomes; D010087:Oxides; D000077237:Arsenic Trioxide; C007740:fluorexon